Search Results
Jun 01, 2026, 14:10 ET PCA SKIN® Launches Triple Exfoliation Peel Pads, Bringing Decades of Professional Peel Expertise Into At-Home Skincare
Dr. Elyse Love, MD, FAAD. "That balance of improving texture, clarity, and radiance without over-stripping the skin, is what makes this technology clinically meaningful
More news about: PCA SKIN
Jun 01, 2026, 11:11 ET Conscientia Health Emerges as a Pioneer in Clinician-Driven AI for Mental Healthcare
MD Anderson Cancer Center. Her extensive background in complex clinical environments and health technology has been instrumental in shaping Conscientia
More news about: Conscientia Health
Jun 01, 2026, 10:42 ET TXOne Networks Positions Enforceable Protection as the Next Evolution of OT Cybersecurity
protection for industrial environments at Gartner Security & Risk Management Summit 2026NATIONAL HARBOR, Md., June 1, 2026 /PRNewswire/ -- TXOne Networks is expanding its visibility-to-protection message at the Gartner
More news about: TXOne Networks USA, Inc.
Jun 01, 2026, 10:38 ET In HelloNation, Family Dentistry Experts Dr. Benjamin Shelton & Dr. Cohloe-Shai Shelton Offer Advice on Bleeding Gums & Gum Disease
an article featuring insights from Dr. Benjamin Shelton and Dr. Cohloe-Shai Shelton of Shelton Family Dental in Baltimore, MD.
More news about: HelloNation
Jun 01, 2026, 10:25 ET Tata Technologies secures SAP PartnerEdge Sell authorization, helps strengthen enterprise and AI-led transformation capabilities
innovations without legacy disruption, ensuring standardized, upgrade stable environments that are agile, scalable, and future ready.Mr. Warren Harris, MD & CEO, Tata Technologies, said, "The future belongs to enterprises that innovate faster, operate smarter, and scale sustainably. Expanding
More news about: Tata Technologies
Jun 01, 2026, 09:24 ET Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
the critical unmet need for a targeted systemic therapy to address the challenging effects of this disease for affected individuals," said Elly Barry, MD, Chief Medical Officer, Day One Biopharmaceuticals, now part of Servier Group. "These encouraging data at ASCO indicate strong promise to support a population
More news about: Servier Pharmaceuticals
Jun 01, 2026, 09:06 ET Benjamin Franklin Plumbing Launches Porcelain Picks Reading Challenge for National Bathroom Reading Month
explore a curated reading list and enter to win $2,000 in cash and a $2,000 library donation.COLUMBIA, Md., June 1, 2026 /PRNewswire/ -- Whether it's a few minutes during a morning routine or a quick break before the
More news about: Benjamin Franklin Plumbing
Jun 01, 2026, 09:01 ET Veritas Aortic Solutions, an inQB8 Spinout, Raises $12M to Advance Non-Surgical Treatment of Aortic Root and Ascending Aortic Diseases
Arshad Quadri, MD and J. Brent Ratz, on the company's Board of Directors."With combined mortality and morbidity rates as high as 65%, it is hard to overstate the risk associated with current surgical treatments for acute conditions of the ascending aorta," said Arshad Quadri MD, Co-Founder, Executive
More news about: Veritas Aortic Solutions
Jun 01, 2026, 09:00 ET Oshi Health Publishes Peer-Reviewed Study of 11,000+ Patients Validating Virtual Multidisciplinary GI Care at Scale
Cohort Study," was authored by Grace Wang, PhD, MPH (Oshi Health); William D. Chey, MD (University of Michigan); Sanskriti Varma, MD (Massachusetts General Hospital, Harvard Medical School); and Sameer K. Berry, MD, MBA (Oshi Health; New York University Grossman School of Medicine). The full paper is
More news about: Oshi Health
Jun 01, 2026, 09:00 ET Choice Hotels International Strengthens Extended Stay Leadership with 30th Everhome Suites Opening
and continued momentum as a front runner in the fast-growing extended stay segmentNORTH BETHESDA, Md., June 1, 2026 /PRNewswire/ -- Choice Hotels International, Inc. (NYSE: CHH), a leader in the
More news about: Choice Hotels International, Inc.
Jun 01, 2026, 09:00 ET Millions of Women Go Through Menopause. Research Hasn't Kept Up.
Dr. Michael Green, MD, Chief Medical Officer at Winona. "The Winona Research Initiative is about investing directly in the next generation of clinicians and researchers
More news about: Winona
Jun 01, 2026, 08:59 ET FRONTERA COMPLETES DIVESTMENT OF ITS COLOMBIAN E&P ASSETS PORTFOLIO TO PAREX RESOURCES; POSITIONS ITSELF AS A STANDALONE INFRASTRUCTURE COMPANY ANNOUNCES RETURN OF CAPITAL DISTRIBUTION TO SHAREHOLDERS
management discussion & analysis dated March 17, 2026, for the year ended December 31, 2025 (the "2025 MD&A"), which information is incorporated by reference herein. A copy of the 2025 MD&A is available under the Company's profile on SEDAR+ at www.sedarplus.ca.
More news about: Frontera Energy Corporation
Jun 01, 2026, 08:11 ET Cancer Vaccine Sustains 49 Percent Melanoma Reduction After 5 Years
Subiaco, Australia; George Ansstas, MD, at Washington University in St. Louis; Matthew Taylor, MD, at the Providence Cancer Institute in Portland, Oregon; Kevin Kim, MD, at the California Pacific Medical Center Research Institute in San Francisco; Meredith McKean, MD, at the Sarah Cannon Research Institute
More news about: NYU Langone Health System
Jun 01, 2026, 08:10 ET McCormick & Company to Report 2026 Second Quarter Financial Results on June 25, 2026
HUNT VALLEY, Md., June 1, 2026 /PRNewswire/ -- McCormick & Company, Incorporated (NYSE: MKC), a global leader in flavor, is scheduled to conduct a conference call and webcast of its second quarter 2026 financial results
More news about: McCormick & Company, Incorporated
Jun 01, 2026, 08:09 ET Sonire Therapeutics Completes Enrollment in SUNRISE-I Randomized Controlled Trial of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
Together, these studies form a global clinical strategy aimed at advancing minimally invasive treatment options for pancreatic cancer.Atsushi Sofuni, MD, Professor of Gastroenterology at Tokyo Medical University and physician who treated the first patient in the SUNRISE-I study, said, "Pancreatic cancer
More news about: Sonire Therapeutics
Jun 01, 2026, 08:03 ET Factor Brings Detection & Response to the Final Frontier: The Supply Chain
decision-making at machine speed to address the industry's biggest cybersecurity challengeNATIONAL HARBOR, Md., June 1, 2026 /PRNewswire/ -- Factor, a cybersecurity company focused on securing the supply chain in the AI
More news about: Factor Cybersecurity
Jun 01, 2026, 08:00 ET Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company
More news about: Actinium Pharmaceuticals, Inc.
Jun 01, 2026, 08:00 ET Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
pathogens. The FDA approval of ZAYNICH is a monumental step forward in validating a new option for these underserved populations," said Dennis Deruelle, MD, FHM, Chief Medical Officer at Wockhardt. "This milestone underscores our commitment to addressing critical unmet needs and offers a profound sense
More news about: Wockhardt
Jun 01, 2026, 07:00 ET Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
in indications that hardly respond to Immuno-Oncology (IO) therapies, such as MSS-CRC, and is currently being evaluated in an ongoing Phase 2 study at MD Anderson Cancer Center.BND-67 is Biond's next-generation immunotherapy and a first-in-class asset targeting CD28 shedding, a novel immune evasion
More news about: Biond Biologics Ltd.; GIBF
Jun 01, 2026, 06:45 ET CGI and Telia announce agreement for business services transfer and new strategic partnership
Environment of CGI's MD&A for the three months and six months ended March 31, 2026 and 2025, which is incorporated by reference in this cautionary statement. We also caution readers that the risks described in the previously mentioned section and in other sections of CGI's MD&A for the three months
More news about: CGI Inc.
Jun 01, 2026, 04:19 ET Sobi to present new data on pegcetacoplan at ERA 2026
deepening our understanding of C3G and primary IC-MPGN and the burden these rare and serious kidney diseases place on patients," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. "The data being presented at ERA 2026 continue to build the evidence supporting
More news about: Swedish Orphan Biotrauma AB
Jun 01, 2026, 03:51 ET Cipla Health touches 1500+ lives through multi-city on-ground screening and awareness initiatives on World No Tobacco Day
and, where required, be guided towards further diagnosis and care. Reinforcing the need for structured cessation support, Mr. Shivam Puri, MD and CEO, Cipla Health Ltd., said, "In India, the intent to quit tobacco is clearly growing, but sustaining that effort continues to remain a challenge.
More news about: Cipla Health
Jun 01, 2026, 00:01 ET ALZHEIMER'S & BRAIN AWARENESS MONTH: TAKE CHARGE OF YOUR BRAIN HEALTH
a new age of Alzheimer's research where we have tests and treatments that can help change the course of this devastating disease," said Paul Aisen, MD, director of the USC Epstein Family Alzheimer's Therapeutic Research Institute and one of the APT Webstudy's lead investigators. "This study allows people
More news about: USC Epstein Family Alzheimer's Therapeutic Research Institute
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry
More news about: Innovent Biologics